Investor Presentaiton
Clinical Pipeline Milestones: 2023 Full-Year Review
23
2023
NDA/BLA/MAA
Submission
HLX10
ES-SCLC1
1L (EU)
HLX10
ES-SCLC
1L (Indonesia, Myanmar, Cambodia,
Malaysia, Thailand, Singapore)
HLX10
nsNSCLC2
1L (China)
HLX10
sqNSCLC³
Final OS results
1L (Pivotal)
HLX07+HLX10
ESCC4
HLX07+HLX10
sqNSCLC
1L, 2L and late-line
1L
Key Clinical Data
Readouts
HLX208
BRAF V600E
LCH/ECD5-22pts
HLX10
nsNSCLC
1L (Pivotal)
HLX07
CSCC6
1L and late-line
1. Extensive stage small cell lung cancer. 2. Non-squamous non-small cell lung cancer. 3. Squamous non-
small cell lung cancer. 4. Esophageal squamous cell carcinoma 5. Langerhans cell histiocytosis (LCH) and
Erdheim-Chester disease (ECD). 6. Cutaneous squamous cell carcinoma
O 2024 Henlius.
Innovative mAb
Innovative small molecule
A Henlius 复宏汉霖View entire presentation